REGN Regeneron Pharmaceuticals, Inc. - Common Stock
$837,77
Kurs · Aug 21, 2026
Fundamentaldaten per Jul 30, 2026
52W-Spanne
$541–$845
98% of range
Analystenbewertung
BUY
37 analysts
Kursziel
$840
+0% upside
P/E (TTM)
20.2
ROE
14.7%
Nettogewinnmarge
31.4%
Über Regeneron Pharmaceuticals, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Das Biotechnologie-Unternehmen Regeneron Pharmaceuticals wurde 1988 gegründet und wird an der Nasdaq-Börse unter dem Symbol „REGN“ gehandelt. Regeneron Pharmaceuticals ist weltweit führend in der Herstellung monoklonaler Antikörper, die Regeneron zum Teil selbst vermarktet, zum Teil aber auch in Lizenz oder Kooperation mit anderen Unternehmen, beispielsweise Bayer oder Sanofi, vertreibt.
Mehr lesen
Das Biotechnologie-Unternehmen Regeneron Pharmaceuticals wurde 1988 gegründet und wird an der Nasdaq-Börse unter dem Symbol „REGN“ gehandelt. Regeneron Pharmaceuticals ist weltweit führend in der Herstellung monoklonaler Antikörper, die Regeneron zum Teil selbst vermarktet, zum Teil aber auch in Lizenz oder Kooperation mit anderen Unternehmen, beispielsweise Bayer oder Sanofi, vertreibt.
Geschichte
Das Unternehmen wurde 1988 von Leonard Schleifer gegründet. Wichtigster Entwickler im Unternehmen ist George Yancopoulos (* 1959), den das Magazin Forbes 2015 als den ersten Milliardär unter den Forschungs- und Entwicklungs-Chefs in der Pharmaindustrie erachtete.
Im Mai 2025 gab das Biotechnologieunternehmen Regeneron Pharmaceuticals bekannt, dass es für 256 Millionen Dollar das Kerngeschäft von 23andMe inklusive Personal Genome Service, Total Health and Research Services und der Biobank übernehmen wolle. Die Übernahme kam nicht zustande.
Produkte
Regeneron Pharmaceuticals ist Marktführer in der Technik, humane Antikörper zu produzieren, und hat eine bedeutende Pipeline experimenteller Kandidaten, beispielsweise zur Behandlung von Krebs, rheumatoider Arthritis und Hypercholesterinämie.
Die strategische Zusammenarbeit mit Sanofi ermöglicht dem Unternehmen eine Langzeitprognose der Finanzierung.
Rilonacept (Handelsname Arcalyst) ist ein Interleukin-1-Inhibitor, d. h. ein antiinflammatorisches Arzneimittel, das zur Behandlung der seltenen Erbkrankheit Cryopyrin-assoziiertes periodisches Syndrom (CAPS) eingesetzt wird. Es war Regenerons erstes Medikament und wurde 2008 in den USA von der Food and Drug Administration (FDA) zugelassen.
Aflibercept ist ein rekombinanter Wachstumsfaktor-Inhibitor, der unter dem Handelsnamen Eylea zur Behandlung der altersbedingten Makuladegeneration (AMD) eingesetzt wird. In Deutschland wird Eylea von Bayer Healthcare Pharmaceuticals vermarktet. Unter dem Handelsnamen Zaltrap wird die gleiche Substanz zur Behandlung des metastasierten kolorektalen Karzinoms eingesetzt. (mCRC). Eylea ist das wichtigste Produkt des Unternehmens.
Praluent (Alirocumab) ist als Proproteinkonvertase-Subtilisin/Kexin-Typ-9-Antikörper zur LDL-Cholesterin-Senkung bei familiärer Hypercholesterinämie zugelassen. Kevzara zur Behandlung der rheumatoiden Arthritis enthält als Wirkstoff den IL-6R-Antikörper Sarilumab.
REGN-COV2 ist eine Kombination aus zwei monoklonalen Antikörpern (Casirivimab (REGN10933) und Imdevimab (REGN10987)) zur passiven Immunisierung nach einer SARS-CoV-2-Infektion. Am 21. November 2020 erteilte die Food and Drug Administration (FDA) eine Notfallzulassung des Medikaments REGN-COV2 für leichte bis mittelschwere Verläufe von COVID-19. Am 24. Januar 2021 gab Bundesgesundheitsminister Jens Spahn bekannt, dass die Bundesregierung 200.000 Dosen für 400 Millionen Euro (= 2000 Euro pro Dosis) gekauft hat. Der Ausschuss für Humanarzneimittel (Human Medicine Committee, CHMP) der Europäischen Arzneimittel-Agentur (EMA) hat am 26. Februar 2021 seine Überprüfung der Verwendung der Kombinationstherapie mit den monoklonalen Antikörpern Casirivimab und Imdevimab zur Behandlung von Patienten mit COVID-19 abgeschlossen.
Sponsoring
Regeneron Pharmaceuticals ist seit 2017 Sponsor des renommierten naturwissenschaftlichen Wettbewerbs für Oberschüler Regeneron Science Talent Search, bei dem zahlreiche Preise bis 250.000 US-Dollar vergeben werden. Das Unternehmen folgt damit Westinghouse (1942 bis 1998) und Intel (1999 bis 2016).
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
REGN Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$837.77
Marktkapitalisierung
$115.53B
P/E (TTM)
20.2
EPS (TTM)
$41.48
Umsatz (TTM)
$14.34B
Dividendenrendite
0.32%
ROE
14.7%
Verschuldungsgrad
0.1
52W-Spanne
$541 – $845
REGN Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$14.34B
2016-12-31
→
2025-12-31
EPS
$41.48
2016-12-31
→
2025-12-31
Freier Cashflow
$4.08B
2016-12-31
→
2025-12-31
Margen
31.4%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
REGN
Peer-Median
P/E (TTM)
20.2
17.7
P/S (TTM) (K/V (TTM))
8.1
6.8
P/B (K/B)
3.7
6.4
EV / EBITDA
26.4
—
Price / FCF (Kurs / FCF)
28.3
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
REGN
Peer-Median
Operating Margin (Betriebsgewinnmarge)
24.9%
—
Net Profit Margin (Nettogewinnmarge)
31.4%
20.3%
ROA
11.5%
11.4%
ROE
14.7%
16.8%
ROIC
9.3%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
REGN
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
0.1
—
Current Ratio (Liquiditätsgrad)
4.1
3.4
Quick Ratio
3.3
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
REGN
Peer-Median
Revenue YoY (Umsatz YoY)
0.99%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
5.6%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
11.0%
—
EPS YoY (EPS VjV)
8.2%
—
Net Income YoY (Nettogewinn YoY)
2.1%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
REGN
Peer-Median
Payout Ratio (Ausschüttungsquote)
8.2%
—
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite
0.32%
Ausschüttungsquote
8.2%
5J Div CAGR
—
| Ex-Datum | Betrag |
|---|---|
| 18. August 2026 | $0,9400 |
| 20. Mai 2026 | $0,9400 |
| 20. Februar 2026 | $0,9400 |
| 20. November 2025 | $0,8800 |
| 18. August 2025 | $0,8800 |
| 20. Mai 2025 | $0,8800 |
| 20. Februar 2025 | $0,8800 |
REGN Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
37 Analysten
- Starker Kauf 8 21,6%
- Kauf 18 48,6%
- Halten 11 29,7%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
27 Analysten · 2026-08-19
Median
$824.00
Jetzt
$837.77
Tief
$730.00
Hoch
$1030.00
Median-Ziel
$824.00
-1,6%
Mittelwert-Ziel
$840.43
+0,3%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
1.7%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $14.29 | $10.47 | 3.8% |
| 31. März 2026 | $9.47 | $9.12 | 0.35% |
| 31. Dezember 2025 | $11.44 | $10.83 | 0.61% |
| 30. September 2025 | $11.83 | $9.78 | 2.0% |
| 30. Juni 2025 | $12.89 | $8.61 | 4.3% |
| 31. März 2025 | $8.22 | $9.00 | -0.78% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| ABBV | — | 96.8 | 8.6% | 6.9% | 15367.3% | — |
| AMGN | $176.35B | 23.0 | 10.0% | 21.0% | 95.9% | — |
| GILD | $152.32B | 18.1 | 2.4% | 28.9% | 40.5% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Cost of Revenue | · | · | · | · | · | · | $403M | $238M | $203M | $195M | $242M | $129M | |
| R&D Expense | $5.85B | $5.13B | $4.44B | $3.59B | $2.86B | $2.65B | $2.45B | $1.47B | $2.08B | $2.05B | $1.62B | $1.27B | |
| SG&A Expense | $2.70B | $2.95B | $2.63B | $2.12B | $1.82B | $1.35B | $1.34B | $1.13B | $1.32B | $1.18B | $839M | $519M | |
| Operating Expenses | $10.77B | $10.21B | $9.07B | $7.43B | $7.12B | $4.92B | $4.35B | $2.61B | $3.79B | $3.53B | $2.85B | $2.00B | |
| Operating Income | $3.58B | $3.99B | $4.05B | $4.74B | $8.95B | $3.58B | $2.21B | $2.53B | $2.08B | $1.33B | $1.25B | $824M | |
| Interest Expense | · | · | $73M | $59M | $57M | $57M | $30M | $28M | $25M | $7M | $14M | $37M | |
| Other Non-op | $1.70B | $844M | $225M | $179M | $436M | $291M | $250M | $47M | $24M | $6M | $-13M | $-25M | |
| Pretax Income | $5.23B | $4.78B | $4.20B | $4.86B | $9.33B | $3.81B | $2.43B | $2.55B | $2.08B | $1.33B | $1.23B | $761M | |
| Income Tax | $726M | $367M | $246M | $520M | $1.25B | $297M | $313M | $109M | $880M | $434M | $589M | $423M | |
| Net Income | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| EPS (Basic) | $43.07 | $40.90 | $37.05 | $40.51 | $76.40 | $32.65 | $19.38 | $22.65 | $11.27 | $8.55 | $6.17 | $3.36 | |
| EPS (Diluted) | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 | $30.52 | $18.46 | $21.29 | $10.34 | $7.70 | $5.52 | $2.98 | |
| Shares (Basic) | 104,600,000 | 107,900,000 | 106,700,000 | 107,100,000 | 105,700,000 | 107,600,000 | 109,200,000 | 107,900,000 | 106,300,000 | 104,700,000 | 103,061,000 | 100,612,000 | |
| Shares (Diluted) | 108,600,000 | 115,100,000 | 113,700,000 | 113,500,000 | 112,200,000 | 115,100,000 | 114,600,000 | 114,800,000 | 115,900,000 | 116,300,000 | 115,230,000 | 113,413,000 | |
| EBITDA | $4.12B | $4.47B | $4.47B | $5.08B | $9.23B | $3.81B | $2.42B | $2.68B | $2.23B | $1.44B | $1.33B | $891M |
Bilanz 27
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B | $813M | $535M | $809M | $649M | |
| Short-term Investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B | $1.60B | $1.34B | $597M | $503M | $236M | $252M | |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B | $1.54B | $1.34B | $1.15B | $739M | |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B | $726M | $399M | $239M | $129M | |
| Prepaid Expense | $475M | $349M | $387M | $411M | $332M | $161M | $274M | $243M | $225M | $131M | $164M | $79M | |
| Current Assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B | $4.33B | $3.18B | $2.92B | $2.08B | |
| PP&E (Net) | · | · | · | · | $3.48B | $3.22B | $2.89B | $2.58B | $2.36B | $2.08B | $1.59B | $974M | |
| PP&E (Gross) | · | · | · | · | · | · | $3.81B | $3.30B | $2.92B | $2.51B | $1.93B | $1.23B | |
| Accum. Depreciation | · | · | · | · | · | · | $922M | $729M | $566M | $426M | $331M | $254M | |
| Intangibles | $1.26B | $1.15B | $1.04B | $916M | $7M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $1.82B | $1.14B | $444M | $336M | $216M | $168M | $145M | $127M | $78M | $20M | $6M | $3M | |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Accounts Payable | $939M | $790M | $607M | $589M | $564M | $476M | $418M | $218M | $178M | $879M | $644M | $483M | |
| Short-term Debt | · | · | · | · | · | · | $0 | · | · | · | · | · | |
| Current Liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B | $1.14B | $1.24B | $811M | $655M | |
| Capital Leases | $229M | $204M | $69M | $56M | · | · | · | $708M | · | · | · | · | |
| Other Non-current Liabilities | $2.02B | $1.57B | $854M | $638M | $680M | $687M | $318M | $362M | $152M | $100M | $116M | $40M | |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B | $2.62B | $2.52B | $1.95B | $1.29B | |
| Total Debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | · | · | · | · | · | · | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $108.0K | $106.0K | $102.0K | |
| Paid-in Capital | $13.99B | $12.86B | $11.35B | $9.95B | $8.09B | $6.72B | $4.43B | $3.91B | $3.51B | $3.03B | $3.10B | $2.45B | |
| Retained Earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B | $2.95B | $1.75B | $853M | $217M | |
| Treasury Stock | $18.61B | $15.17B | $12.56B | $10.35B | $8.26B | $6.61B | $740M | $396M | $316M | $316M | $306M | $170M | |
| AOCI | $78M | $-8M | $-81M | $-239M | $-26M | $29M | $21M | $-12M | $600.0K | $-13M | $9M | $52M | |
| Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B | $6.14B | $4.45B | $3.65B | $2.55B | |
| Liabilities + Equity | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B | $8.76B | $6.97B | $5.61B | $3.84B | |
| Shares Outstanding | 137,600,000 | 136,000,000 | 133,100,000 | 130,400,000 | 126,200,000 | 121,500,000 | 113,300,000 | · | · | · | · | · |
Cashflow 19
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $544M | $483M | $421M | $341M | $286M | $236M | $210M | $148M | $146M | $105M | $75M | $53M | |
| Stock-based Comp | $994M | $983M | $885M | $725M | $602M | $432M | $464M | $427M | $507M | $560M | $459M | $322M | |
| Deferred Tax | $-785M | $-757M | $-838M | $-746M | $-147M | $76M | $-131M | $-140M | $319M | $-360M | $-130M | $-46M | |
| Amort. of Intangibles | $179M | $129M | $92M | $38M | $0 | · | · | · | · | · | · | · | |
| Other Non-cash | $-278M | $-700M | $172M | $356M | $-1.73B | $-1.64B | $-230M | $-685M | $-863M | $273M | $291M | $86M | |
| Operating Cash Flow | $4.98B | $4.42B | $4.59B | $5.01B | $7.08B | $2.62B | $2.43B | $2.20B | $1.31B | $1.49B | $1.33B | $752M | |
| CapEx | $898M | $756M | $719M | $590M | $552M | $615M | $430M | $383M | $273M | $512M | $678M | $333M | |
| Investing Cash Flow | $-629M | $-2.47B | $-3.19B | $-3.78B | $-5.38B | $-71M | $-2.03B | $-1.46B | $-1.01B | $-1.05B | $-908M | $-421M | |
| Debt Issued | · | · | · | $0 | $0 | $1.98B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | · | · | · | $0 | $0 | $1.98B | · | · | · | · | · | · | |
| Stock Issued | $636M | $1.47B | $1.15B | $1.52B | $1.67B | $2.58B | $212M | $114M | $240M | $127M | $206M | $126M | |
| Stock Repurchased | $3.44B | $2.60B | $2.23B | $2.08B | $1.65B | $5.85B | $276M | $4M | $0 | $0 | · | · | |
| Net Stock Activity | $-2.80B | $-1.14B | $-1.09B | $-563M | $27M | $-3.27B | $-64M | $110M | $240M | $127M | $206M | $126M | |
| Dividends Paid | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-3.72B | $-2.20B | $-1.79B | $-1.01B | $-1.01B | $-1.97B | $-252M | $-77M | $-24M | $-700M | $-263M | $-219M | |
| Net Change in Cash | $635M | $-249M | $-382M | $221M | $691M | $577M | $150M | $655M | $278M | $-261M | $160M | $113M | |
| Taxes Paid | $1.25B | $743M | $870M | $1.50B | $1.22B | $188M | $342M | $206M | $755M | $481M | $276M | $60M | |
| Free Cash Flow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B | $2.00B | $2.00B | $1.81B | $1.03B | $961M | $653M | $410M | |
| Levered FCF | · | · | $3.81B | $4.37B | $6.48B | $1.95B | $1.97B | $1.79B | · | · | $645M | $393M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% | 42.1% | 28.1% | 37.8% | 35.4% | 27.4% | 30.5% | 29.7% | |
| Net Margin | 31.4% | 31.1% | 30.1% | 35.6% | 50.2% | 41.3% | 26.9% | 36.4% | 20.4% | 18.4% | 15.5% | 12.3% | |
| Pretax Margin | 36.5% | 33.7% | 32.0% | 39.9% | 58.0% | 44.8% | 30.9% | 38.0% | 35.4% | 27.4% | 29.8% | 27.5% | |
| EBITDA Margin | 28.7% | 31.5% | 34.1% | 41.7% | 57.5% | 44.9% | 30.8% | 40.0% | 37.9% | 29.5% | 32.3% | 31.6% | |
| ROA | 11.5% | 12.5% | 12.7% | 15.9% | 37.9% | 22.0% | 15.9% | 23.8% | 15.2% | 14.2% | 13.5% | 10.2% | |
| ROE | 14.7% | 15.0% | 15.5% | 19.7% | 44.8% | 33.2% | 19.6% | 29.4% | 22.6% | 22.1% | 20.5% | 15.4% | |
| ROIC | 9.3% | 11.8% | 13.6% | 17.2% | 37.3% | 25.4% | 17.4% | 27.7% | 19.5% | 20.1% | 17.8% | 14.8% |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 | 3.6 | 3.7 | 4.5 | 3.8 | 2.6 | 3.6 | 3.3 | |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 | 2.5 | 2.5 | 3.1 | 2.6 | 1.9 | 2.7 | 2.5 | |
| Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| LT Debt / Equity | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | 55.4 | 79.8 | 156.1 | 62.9 | 73.2 | 89.9 | · | · | 87.9 | 22.4 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.5 | 0.6 | 0.7 | 0.7 | 0.8 | 0.9 | 0.8 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 0.4 | 0.6 | 1.3 | 1.3 | |
| Receivables Turnover | 2.4 | 2.4 | 2.4 | 2.1 | 3.2 | 3.3 | 4.1 | 4.1 | 4.1 | 3.9 | 4.3 | 3.7 |
Wachstumsraten 9
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 0.99% | 8.3% | 7.8% | -24.3% | 89.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.6% | -4.0% | 15.6% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 8.2% | 10.3% | -9.0% | -46.9% | 135.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 2.8% | -18.9% | 4.4% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 2.1% | 11.6% | -8.9% | -46.3% | 129.9% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.3% | -18.2% | 4.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 5.1% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B | $8.50B | $6.56B | $5.15B | $5.87B | $4.86B | $4.10B | $2.82B | |
| Net Income TTM | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B | $3.51B | $2.12B | $2.44B | $1.20B | $896M | $636M | $338M | |
| Market Cap | $106.21B | $96.88B | $116.90B | $94.08B | · | · | · | · | · | · | · | · | |
| Enterprise Value | $99.59B | $89.85B | $108.04B | $88.32B | · | · | · | · | · | · | · | · | |
| P/E | 18.6 | 18.6 | 25.3 | 18.9 | 8.8 | 15.8 | 20.3 | 17.5 | 36.4 | 47.7 | 98.3 | 137.7 | |
| P/S | 7.4 | 6.8 | 8.9 | 7.7 | · | · | · | · | · | · | · | · | |
| P/B | 3.4 | 3.3 | 4.5 | 4.2 | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 3.5 | 3.4 | 4.7 | 4.3 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 21.3 | 21.9 | 25.4 | 18.8 | · | · | · | · | · | · | · | · | |
| P / FCF | 26.0 | 26.4 | 30.2 | 21.3 | · | · | · | · | · | · | · | · | |
| EV / EBITDA | 24.2 | 20.1 | 24.2 | 17.4 | · | · | · | · | · | · | · | · | |
| EV / FCF | 24.4 | 24.5 | 27.9 | 20.0 | · | · | · | · | · | · | · | · | |
| EV / Revenue | 6.9 | 6.3 | 8.2 | 7.3 | · | · | · | · | · | · | · | · | |
| Dividend Yield | 0.35% | 0.00% | 0.00% | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 5.4% | 5.4% | 4.0% | 5.3% | 11.4% | 6.3% | 4.9% | 5.7% | 2.8% | 2.1% | 1.0% | 0.73% | |
| Payout Ratio | 8.2% | · | · | · | · | · | · | · | · | · | · | · | |
| Annual Payout | $370M | $0 | $0 | · | · | · | · | · | · | · | · | · |
Gewinn- und Verlustrechnung 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.29B | $3.61B | $3.88B | $3.75B | $3.68B | $3.03B | $3.79B | $3.72B | $3.55B | $3.15B | $3.43B | $3.36B | $3.16B | $3.16B | $3.41B | $2.94B | |
| R&D Expense | $1.63B | $1.54B | $1.63B | $1.48B | $1.42B | $1.33B | $1.41B | $1.27B | $1.20B | $1.25B | $1.18B | $1.08B | $1.09B | $1.10B | $1.04B | $911M | |
| SG&A Expense | $662M | $648M | $775M | $658M | $634M | $633M | $792M | $714M | $759M | $689M | $738M | $640M | $652M | $601M | $660M | $529M | |
| Operating Expenses | $3.00B | $2.96B | $3.00B | $2.73B | $2.60B | $2.44B | $2.80B | $2.54B | $2.48B | $2.39B | $2.46B | $2.25B | $2.14B | $2.22B | $2.27B | $1.71B | |
| Operating Income | $1.29B | $643M | $880M | $1.03B | $1.08B | $592M | $990M | $1.18B | $1.07B | $751M | $973M | $1.11B | $1.02B | $947M | $1.15B | $1.22B | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $16M | · | $18M | $19M | $18M | · | $15M | |
| Other Non-op | $245M | $201M | $176M | $756M | $443M | $322M | $-22M | $327M | $573M | $-35M | $193M | $18M | $85M | $-71M | $195M | $301M | |
| Pretax Income | $1.53B | $831M | $1.04B | $1.76B | $1.52B | $905M | $958M | $1.49B | $1.63B | $701M | $1.15B | $1.11B | $1.08B | $858M | $1.32B | $1.51B | |
| Income Tax | $231M | $104M | $199M | $303M | $127M | $96M | $40M | $152M | $196M | $-21M | $-12M | $103M | $114M | $40M | $128M | $194M | |
| Net Income | $1.30B | $727M | $845M | $1.46B | $1.39B | $809M | $918M | $1.34B | $1.43B | $722M | $1.16B | $1.01B | $968M | $818M | $1.20B | $1.32B | |
| EPS (Basic) | $12.62 | $6.99 | $8.16 | $14.09 | $13.24 | $7.58 | $8.55 | $12.40 | $13.25 | $6.70 | $10.88 | $9.48 | $9.05 | $7.64 | $11.18 | $12.31 | |
| EPS (Diluted) | $12.23 | $6.75 | $7.78 | $13.62 | $12.81 | $7.27 | $8.12 | $11.54 | $12.41 | $6.27 | $10.21 | $8.89 | $8.50 | $7.17 | $10.48 | $11.66 | |
| Shares (Basic) | 102,800,000 | 104,000,000 | -210,800,000 | 103,600,000 | 105,100,000 | 106,700,000 | -216,100,000 | 108,100,000 | 108,100,000 | 107,800,000 | -213,700,000 | 106,300,000 | 107,000,000 | 107,100,000 | -214,500,000 | 106,900,000 | |
| Shares (Diluted) | 106,000,000 | 107,700,000 | -218,400,000 | 107,200,000 | 108,600,000 | 111,200,000 | -231,600,000 | 116,200,000 | 115,400,000 | 115,100,000 | -227,600,000 | 113,400,000 | 113,900,000 | 114,000,000 | -226,400,000 | 112,800,000 | |
| EBITDA | $1.29B | $766M | · | $1.03B | $1.08B | $719M | · | $1.18B | $1.07B | $866M | · | $1.11B | $1.02B | $1.05B | · | $1.22B |
Bilanz 24
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.46B | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B | $2.60B | $2.73B | $2.15B | $1.94B | $3.92B | $3.11B | $3.49B | |
| Short-term Investments | $5.54B | $5.79B | $5.49B | $5.94B | $5.47B | $5.26B | $6.52B | $7.78B | $7.89B | $7.92B | · | $7.76B | $6.99B | $5.04B | · | $3.53B | |
| Receivables | $6.57B | $5.73B | $5.74B | $5.69B | $5.61B | $5.56B | $6.21B | $6.11B | $5.72B | $5.22B | · | $5.58B | $5.12B | $5.12B | · | $5.55B | |
| Inventory | $3.08B | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B | $3.02B | $2.87B | $2.71B | · | $2.56B | $2.51B | $2.42B | · | $2.41B | |
| Prepaid Expense | $802M | $621M | $475M | $596M | $574M | $469M | $349M | $412M | $682M | $415M | · | $575M | $366M | $406M | · | $446M | |
| Current Assets | $18.45B | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B | $19.33B | $19.08B | $18.87B | · | $18.63B | $16.92B | $16.91B | · | $15.43B | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $3.70B | |
| Intangibles | $1.31B | $1.29B | $1.26B | $1.38B | $1.35B | $1.17B | $1.15B | $1.12B | $1.10B | $1.06B | · | $1.02B | $953M | $929M | · | $804M | |
| Other Non-current Assets | $2.31B | $2.13B | $1.82B | $1.67B | $1.54B | $1.39B | $1.14B | $1.04B | $994M | $470M | · | $410M | $393M | $350M | · | $320M | |
| Total Assets | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Accounts Payable | $1.16B | $1.03B | $939M | $904M | $724M | $706M | $790M | $497M | $562M | $671M | · | $537M | $547M | $600M | · | · | |
| Current Liabilities | $5.53B | $5.11B | $4.37B | $4.43B | $3.67B | $3.57B | $3.94B | $3.66B | $3.51B | $3.58B | · | $3.60B | $3.10B | $3.10B | · | $2.88B | |
| Capital Leases | · | · | $229M | · | · | · | $204M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.28B | $2.13B | $2.02B | $1.86B | $1.70B | $1.67B | $1.57B | $1.54B | $1.46B | $908M | · | $832M | $717M | $677M | · | $599M | |
| Total Liabilities | $10.02B | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B | $7.38B | · | $7.26B | $6.64B | $6.56B | · | $6.24B | |
| Total Debt | $1.99B | $1.99B | · | $1.99B | $1.99B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | $1.98B | $1.98B | · | $1.98B | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $14.70B | $14.40B | $13.99B | $13.79B | $13.49B | $13.19B | $12.86B | $12.70B | $12.32B | $11.94B | · | $11.25B | $10.89B | $10.60B | · | $9.52B | |
| Retained Earnings | $37.62B | $36.42B | $35.80B | $35.05B | $33.68B | $32.38B | $31.67B | $30.76B | $29.41B | $27.98B | · | $26.10B | $25.09B | $24.12B | · | $22.11B | |
| Treasury Stock | $20.57B | $19.41B | $18.61B | $17.94B | $17.28B | $16.22B | $15.17B | $14.19B | $13.46B | $12.86B | · | $12.27B | $11.77B | $11.05B | · | $9.91B | |
| AOCI | $-36M | $12M | $78M | $69M | $52M | $29M | $-8M | $60M | $-70M | $-77M | · | $-177M | $-198M | $-182M | · | $-275M | |
| Stockholders' Equity | $31.71B | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B | $26.99B | $25.97B | $24.90B | $24.02B | $23.50B | $22.66B | $21.44B | |
| Liabilities + Equity | $41.73B | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B | $34.37B | · | $32.16B | $30.66B | $30.06B | · | $27.68B | |
| Shares Outstanding | 138,000,000 | 137,900,000 | 137,600,000 | 136,200,000 | 136,200,000 | 136,100,000 | 136,000,000 | 135,300,000 | 134,800,000 | 134,200,000 | 133,100,000 | 132,100,000 | 131,600,000 | 131,400,000 | 130,400,000 | 129,000,000 |
Cashflow 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $124M | $123M | $145M | $137M | $135M | $127M | $126M | $122M | $121M | $114M | $113M | $105M | $103M | $100M | $100M | $93M | |
| Stock-based Comp | $243M | $257M | $249M | $237M | $252M | $256M | $304M | $225M | $223M | $230M | $240M | $204M | $202M | $239M | $232M | $166M | |
| Amort. of Intangibles | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $21M | $16M | |
| Other Non-cash | · | $-29M | · | · | · | $-146M | · | · | · | $446M | · | · | · | $212M | · | · | |
| Operating Cash Flow | $813M | $1.08B | $1.17B | $1.62B | $1.14B | $1.05B | $1.26B | $1.29B | $354M | $1.51B | $1.09B | $1.11B | $1.02B | $1.37B | $1.72B | $629M | |
| CapEx | $240M | $231M | $249M | $201M | $219M | $229M | $200M | $242M | $180M | $134M | $251M | $176M | $113M | $178M | $152M | $142M | |
| Investing Cash Flow | $-93M | $-429M | $220M | $-403M | $-1.09B | $648M | $351M | $-574M | $-557M | $-1.69B | $-66M | $-496M | $-2.39B | $-236M | $-1.86B | $192M | |
| Stock Issued | $49M | $163M | $504M | $40M | $32M | $61M | $91M | $255M | $438M | $682M | $301M | $269M | $91M | $485M | $373M | $318M | |
| Stock Repurchased | $1.17B | $794M | $672M | $664M | $1.06B | $1.04B | $973M | $735M | $604M | $291M | $289M | $546M | $689M | $711M | $431M | $935M | |
| Net Stock Activity | · | $-631M | · | · | · | $-981M | · | · | · | $391M | · | · | · | $-226M | · | · | |
| Dividends Paid | $97M | $98M | $93M | $91M | $93M | $94M | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.22B | $-802M | $-780M | $-718M | $-1.13B | $-1.09B | $-1.14B | $-634M | $-478M | $47M | $-446M | $-407M | $-614M | $-322M | $-248M | $-725M | |
| Net Change in Cash | $-505M | $-153M | $611M | $498M | $-1.08B | $604M | $477M | $84M | $-682M | $-128M | $578M | $210M | $-1.98B | $809M | $-385M | $96M | |
| Free Cash Flow | · | $848M | · | · | · | $816M | · | · | · | $1.38B | · | · | · | $1.19B | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $1.36B | · | · | · | $1.17B | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 30.1% | 17.8% | · | 27.4% | 29.4% | 19.5% | · | 31.7% | 30.1% | 23.9% | · | 33.0% | 32.2% | 29.9% | · | 41.7% | |
| Net Margin | 30.2% | 20.2% | · | 38.9% | 37.9% | 26.7% | · | 36.0% | 40.4% | 23.0% | · | 30.0% | 30.7% | 25.9% | · | 44.8% | |
| Pretax Margin | 35.6% | 23.1% | · | 47.0% | 41.3% | 29.9% | · | 40.1% | 45.9% | 22.3% | · | 33.0% | 34.3% | 27.1% | · | 51.4% | |
| EBITDA Margin | 30.1% | 21.2% | · | 27.4% | 29.4% | 23.7% | · | 31.7% | 30.1% | 27.5% | · | 33.0% | 32.2% | 33.1% | · | 41.7% | |
| ROA | 3.2% | 1.8% | · | 3.8% | 3.8% | 2.2% | · | 3.9% | 4.3% | 2.2% | · | 3.4% | 3.4% | 2.9% | · | 5.1% | |
| ROE | 4.2% | 2.4% | · | 4.8% | 4.8% | 2.9% | · | 4.9% | 5.5% | 2.9% | · | 4.3% | 4.3% | 3.8% | · | 6.8% | |
| ROIC | 3.3% | 1.7% | · | 2.6% | 3.1% | 1.7% | · | 3.4% | 3.1% | 2.7% | · | 3.8% | 3.5% | 3.5% | · | 4.5% |
Liquidität & Solvenz 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.3 | 3.6 | · | 4.1 | 4.6 | 4.9 | · | 5.3 | 5.4 | 5.3 | · | 5.2 | 5.5 | 5.5 | · | 5.4 | |
| Quick Ratio | 2.6 | 2.8 | · | 3.2 | 3.6 | 3.9 | · | 4.3 | 4.4 | 4.4 | · | 4.3 | 4.5 | 4.5 | · | 4.4 | |
| Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| LT Debt / Equity | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 46.7 | · | 62.4 | 53.8 | 52.6 | · | 80.0 |
Effizienz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.7 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.5 |
Bewertung (TTM) 15
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $15.33B | $14.06B | · | $14.18B | $13.97B | $13.44B | · | $13.78B | $13.21B | $12.83B | · | $12.62B | $12.11B | $11.92B | · | $12.21B | |
| Net Income TTM | $4.88B | $4.39B | · | $5.00B | $4.97B | $4.30B | · | $4.50B | $4.13B | $3.52B | · | $4.11B | $3.95B | $3.96B | · | $4.77B | |
| Market Cap | $86.05B | $106.55B | · | $76.58B | $71.50B | $86.32B | · | $142.23B | $141.68B | $129.17B | · | $108.71B | $94.56B | $107.97B | · | $88.86B | |
| Enterprise Value | $80.04B | $99.78B | · | $70.12B | $66.02B | $79.95B | · | $134.42B | $133.85B | $120.63B | · | $100.78B | $87.61B | $100.99B | · | $83.82B | |
| P/E | 13.7 | 19.1 | · | 12.4 | 11.9 | 16.9 | · | 26.9 | 29.1 | 31.2 | · | 22.7 | 20.6 | 23.5 | · | 16.4 | |
| P/S | 5.6 | 7.6 | · | 5.4 | 5.1 | 6.4 | · | 10.3 | 10.7 | 10.1 | · | 8.6 | 7.8 | 9.1 | · | 7.3 | |
| P/B | 2.7 | 3.4 | · | 2.5 | 2.4 | 2.9 | · | 4.9 | 5.0 | 4.8 | · | 4.4 | 3.9 | 4.6 | · | 4.1 | |
| P / Tangible Book | 2.8 | 3.5 | · | 2.6 | 2.5 | 3.1 | · | 5.0 | 5.2 | 5.0 | · | 4.6 | 4.1 | 4.8 | · | 4.3 | |
| P / Cash Flow | · | 98.8 | · | · | · | 82.6 | · | · | · | 85.4 | · | · | · | 78.9 | · | · | |
| P / FCF | · | 125.6 | · | · | · | 105.8 | · | · | · | 93.7 | · | · | · | 90.8 | · | · | |
| EV / EBITDA | 61.9 | 130.2 | · | 68.3 | 61.2 | 111.3 | · | 114.0 | 125.1 | 139.4 | · | 90.7 | 86.2 | 96.5 | · | 68.5 | |
| EV / FCF | · | 117.6 | · | · | · | 98.0 | · | · | · | 87.5 | · | · | · | 84.9 | · | · | |
| EV / Revenue | 5.2 | 7.1 | · | 4.9 | 4.7 | 5.9 | · | 9.8 | 10.1 | 9.4 | · | 8.0 | 7.2 | 8.5 | · | 6.9 | |
| Earnings Yield | 7.3% | 5.2% | · | 8.1% | 8.4% | 5.9% | · | 3.7% | 3.4% | 3.2% | · | 4.4% | 4.8% | 4.2% | · | 6.1% | |
| Payout Ratio | · | 13.5% | · | · | · | 11.6% | · | · | · | · | · | · | · | · | · | · |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $14.34B | $14.20B | $13.12B | $12.17B | $16.07B |
| Betriebsgewinnmarge % | 24.9% | 28.1% | 30.9% | 38.9% | 55.7% |
| Nettoergebnis | $4.50B | $4.41B | $3.95B | $4.34B | $8.08B |
| Verwässerte EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Liquiditätsgrad | 4.1 | 4.7 | 5.7 | 5.1 | 3.6 |
| Quick Ratio | 3.3 | 3.9 | 4.8 | 4.2 | 3.0 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $4.08B | $3.66B | $3.88B | $4.42B | $6.53B |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
- FDG's Holdings implizieren ein Gewinnpotenzial von 20 %
- iShares MSCI USA Min Vol Factor ETF verzeichnet große Abflüsse
- Regeneron Pharmaceuticals (REGN) kündigt Zusammenarbeit mit Telix Pharmaceuticals Limited an
- Gewinnvorschau: Was von Regeneron Pharmaceuticals' Bericht zu erwarten ist
- Regeneron Pharma schließt Partnerschaft mit Telix Pharma zur gemeinsamen Entwicklung radiopharmazeutischer Therapien
- Jim Cramer über Regeneron (REGN): "Ich denke, die Aktie bricht hier aus"
- Telix und Regeneron kooperieren zur Weiterentwicklung von Radiopharmazeutika der nächsten Generation
- Formycon sichert sich Europa-Starttermin für FYB203 nach Einigung mit Regeneron und Bayer
- Ist Regeneron Pharmaceuticals, Inc. (REGN) eine gute Aktie zum Kaufen?
Handelssignale Aktuelle Kauf-/Verkaufssignale mit Einstiegspreis und Risiko-Ertrags-Verhältnis
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 1.481 Einreicher · $34.8B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 116 (-46 vs. Vorquartal) | 163 (+66 vs. Vorquartal) | 487 (-65 vs. Vorquartal) | 534 (+50 vs. Vorquartal) | -156K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $4.133.919.926 | 6.629.759 | 11,89% | Aktien |
| Dodge & Cox | $3.037.348.765 | 4.871.137 | 8,73% | Aktien |
| STATE STREET CORP | $3.014.621.356 | 4.834.688 | 8,67% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.979.934.668 | 3.175.313 | 5,69% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $1.427.303.015 | 2.297.074 | 4,10% | Aktien |
| LOOMIS SAYLES & CO L P | $1.014.501.372 | 1.627.003 | 2,92% | Aktien |
| PeakShares LLC | $975.217.000 | 1.564 | 2,80% | Aktien |
| WELLINGTON MANAGEMENT GROUP LLP | $763.126.911 | 1.223.862 | 2,19% | Aktien |
| NORGES BANK | $731.292.700 | 1.172.808 | 2,10% | Aktien |
| Capital World Investors | $508.138.359 | 814.925 | 1,46% | Aktien |
| TWO SIGMA ADVISERS, LP | $466.626.290 | 604.540 | 1,34% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $432.674.406 | 693.900 | 1,24% | Verkaufsoption |
| TWO SIGMA INVESTMENTS, LP | $409.119.559 | 656.124 | 1,18% | Aktien |
| GOLDMAN SACHS GROUP INC | $392.576.914 | 629.594 | 1,13% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $351.496.357 | 563.711 | 1,01% | Aktien |
| FIRST TRUST ADVISORS LP | $341.158.711 | 547.132 | 0,98% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $299.532.285 | 480.373 | 0,86% | Aktien |
| Robeco Institutional Asset Management B.V. | $287.203.770 | 460.602 | 0,83% | Aktien |
| NEUBERGER BERMAN GROUP LLC | $259.935.179 | 416.870 | 0,75% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $249.320.598 | 399.847 | 0,72% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $245.478.345 | 393.685 | 0,71% | Aktien |
| National Pension Service | $236.829.845 | 379.815 | 0,68% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $236.259.306 | 378.900 | 0,68% | Kaufoption |
| ALLIANCEBERNSTEIN L.P. | $225.872.032 | 292.338 | 0,65% | Aktien |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $220.714.454 | 353.970 | 0,63% | Aktien |
| BlackRock, Inc. | $207.677.479 | 333.062 | 0,60% | Aktien |
| JANE STREET GROUP, LLC | $198.659.844 | 318.600 | 0,57% | Kaufoption |
| Swiss National Bank | $182.709.691 | 293.020 | 0,53% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $175.962.364 | 282.199 | 0,51% | Aktien |
| BANK OF AMERICA CORP /DE/ | $171.791.505 | 275.510 | 0,49% | Aktien |
| CITADEL ADVISORS LLC | $169.166.402 | 271.300 | 0,49% | Kaufoption |
| FIL Ltd | $165.543.635 | 265.490 | 0,48% | Aktien |
| CITADEL ADVISORS LLC | $164.988.684 | 264.600 | 0,47% | Verkaufsoption |
| FMR LLC | $162.474.852 | 260.568 | 0,47% | Aktien |
| TD Asset Management Inc | $161.694.522 | 259.317 | 0,46% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $160.530.373 | 257.450 | 0,46% | Aktien |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $159.939.881 | 256.503 | 0,46% | Aktien |
| Nuveen, LLC | $158.965.911 | 254.941 | 0,46% | Aktien |
| Caisse de depot et placement du Quebec | $156.264.112 | 250.608 | 0,45% | Aktien |
| Assenagon Asset Management S.A. | $152.721.782 | 244.927 | 0,44% | Aktien |
| Vanguard Global Advisers, LLC | $141.371.483 | 226.724 | 0,41% | Aktien |
| California Public Employees Retirement System | $139.840.692 | 224.269 | 0,40% | Aktien |
| Qube Research & Technologies Ltd | $138.180.829 | 221.607 | 0,40% | Aktien |
| Legal & General Group Plc | $134.385.341 | 215.520 | 0,39% | Aktien |
| CANADA PENSION PLAN INVESTMENT BOARD | $130.887.905 | 209.911 | 0,38% | Aktien |
| Squarepoint Ops LLC | $123.814.467 | 198.567 | 0,36% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $123.317.506 | 197.770 | 0,35% | Aktien |
| Candriam S.C.A. | $121.893.176 | 195.674 | 0,35% | Aktien |
| MCDONALD CAPITAL INVESTORS INC/CA | $120.366.915 | 193.038 | 0,35% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $119.141.861 | 154.201 | 0,34% | Aktien |
| Swedbank AB | $118.377.821 | 189.848 | 0,34% | Aktien |
| Carmignac Gestion | $113.826.706 | 182.507 | 0,33% | Aktien |
| BANK OF NOVA SCOTIA | $113.300.959 | 181.706 | 0,33% | Aktien |
| JANE STREET GROUP, LLC | $112.548.970 | 180.500 | 0,32% | Verkaufsoption |
| BARCLAYS PLC | $111.306.254 | 178.507 | 0,32% | Aktien |
| PANAGORA ASSET MANAGEMENT INC | $109.300.950 | 175.291 | 0,31% | Aktien |
| GOLDMAN SACHS GROUP INC | $106.687.694 | 171.100 | 0,31% | Kaufoption |
| MILLENNIUM MANAGEMENT LLC | $102.958.925 | 165.120 | 0,30% | Aktien |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $102.237.489 | 163.963 | 0,29% | Aktien |
| Bronte Capital Management Pty Ltd. | $101.398.828 | 162.618 | 0,29% | Aktien |
| NORDEA INVESTMENT MANAGEMENT AB | $100.247.789 | 160.258 | 0,29% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $99.201.835 | 159.095 | 0,29% | Aktien |
| RHUMBLINE ADVISERS | $98.390.781 | 157.794 | 0,28% | Aktien |
| Pictet Asset Management Holding SA | $96.459.212 | 153.500 | 0,28% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $92.422.346 | 148.222 | 0,27% | Aktien |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $92.259.602 | 147.961 | 0,27% | Aktien |
| AMERIPRISE FINANCIAL INC | $90.305.429 | 144.827 | 0,26% | Aktien |
| MACKENZIE FINANCIAL CORP | $84.666.132 | 135.783 | 0,24% | Aktien |
| PRUDENTIAL FINANCIAL INC | $81.380.076 | 130.513 | 0,23% | Aktien |
| Retirement Systems of Alabama | $79.731.436 | 127.869 | 0,23% | Aktien |
| MARSHALL WACE, LLP | $79.189.580 | 127.000 | 0,23% | Verkaufsoption |
| Sound Shore Management Inc /CT/ | $79.185.839 | 126.994 | 0,23% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $78.779.916 | 126.343 | 0,23% | Aktien |
| ProShare Advisors LLC | $74.350.910 | 119.240 | 0,21% | Aktien |
| NEW YORK STATE COMMON RETIREMENT FUND | $69.443.026 | 111.369 | 0,20% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $68.488.193 | 109.838 | 0,20% | Aktien |
| Gotham Asset Management, LLC | $65.574.584 | 105.165 | 0,19% | Aktien |
| Harvest Portfolios Group Inc. | $65.232.261 | 104.616 | 0,19% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $62.737.149 | 100.286 | 0,18% | Aktien |
| Mariner, LLC | $61.632.002 | 98.826 | 0,18% | Aktien |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $61.471.693 | 98.585 | 0,18% | Aktien |
| PARNASSUS INVESTMENTS, LLC | $59.471.998 | 95.378 | 0,17% | Aktien |
| Davern Capital Partners, LP | $57.764.746 | 92.640 | 0,17% | Aktien |
| AVIVA PLC | $57.045.180 | 91.486 | 0,16% | Aktien |
| PFA Pension, Forsikringsaktieselskab | $56.561.245 | 90.710 | 0,16% | Aktien |
| ARMISTICE CAPITAL, LLC | $55.999.504 | 89.809 | 0,16% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $54.996.852 | 88.201 | 0,16% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $52.429.737 | 84.084 | 0,15% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $52.158.497 | 83.649 | 0,15% | Aktien |
| ROYAL BANK OF CANADA | $51.450.000 | 82.513 | 0,15% | Aktien |
| CWM, LLC | $51.303.491 | 66.400 | 0,15% | Aktien |
| PINNACLE ASSOCIATES LTD | $50.660.926 | 81.247 | 0,15% | Aktien |
| GROUPAMA ASSET MANAGMENT | $49.128.285 | 77.940 | 0,14% | Aktien |
| NEOS Investment Management LLC | $48.213.359 | 77.322 | 0,14% | Aktien |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | $46.765.500 | 75.000 | 0,13% | Aktien |
| Korea Investment CORP | $46.737.441 | 74.955 | 0,13% | Aktien |
| Grantham, Mayo, Van Otterloo & Co. LLC | $46.266.668 | 74.200 | 0,13% | Aktien |
| WOLVERINE TRADING, LLC | $45.925.425 | 81.900 | 0,13% | Kaufoption |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $45.875.500 | 59.375 | 0,13% | Aktien |
| Woodline Partners LP | $45.265.886 | 72.595 | 0,13% | Aktien |
Unternehmensinsider 39 Insider · 4 Führungskräfte · 7 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | 31. Dezember 2025 M | 214.523 | 0 | 0 | $0 |
| Christopher R. Fenimore | EVP Finance CFO | 18. August 2026 M | 19.984 | 0 | 0 | $0 |
| Joseph J Larosa | EVP General Counsel and Secret | 19. August 2026 M | 36.373 | 0 | 0 | $0 |
| Van Plew Daniel P | EVP & General Mgr, Industrial | 9. Dezember 2025 F | 21.673 | 0 | 0 | $0 |
| Arthur F Ryan | Direktor | 2. Juli 2026 S | 17.303 | 0 | 48 | $-434.683 |
| Craig B. Thompson | Direktor | 2. Januar 2026 A | 775 | 0 | 0 | $0 |
| Anthony N Coles | Direktor | 2. Januar 2026 A | 1.714 | 0 | 0 | $0 |
| Christine A Poon | Direktor | 2. Januar 2026 A | 5.219 | 0 | 6 | $-4.252.745 |
| Michael S Brown | Direktor | 2. Januar 2026 A | 1.703 | 0 | 0 | $0 |
| David P Schenkein | Direktor | 8. September 2023 A | 240 | 0 | 0 | $0 |
| REGENERON PHARMACEUTICALS, INC. | 10%-Eigentümer | 17. Februar 2021 C | 2.097.314 | 0 | 0 | $0 |
| Sanofi | 10%-Eigentümer | 9. Juni 2020 S | 279.766 | 0 | 0 | $0 |
| Pharma Ag Novartis | 10%-Eigentümer | 8. November 2005 S | — | 0 | 0 | $0 |
| Kathryn Guarini | — | 10. August 2026 M | 603 | 0 | 1 | $-320.000 |
| Huda Y Zoghbi | — | 10. August 2026 M | 1.703 | 0 | 1 | $-640.000 |
| Joseph L Goldstein | — | 2. Januar 2026 A | 6.703 | 0 | 0 | $0 |
| George L Sing | — | 2. Januar 2026 A | 31.007 | 0 | 0 | $0 |
| George Yancopoulos | — | 31. Dezember 2025 M | 310.460 | 0 | 0 | $0 |
| Marc Tessier-Lavigne | — | 9. Dezember 2021 M | 2.078 | 0 | 0 | $0 |
| Marion Mccourt | — | 7. Juni 2021 M | 17.038 | 0 | 0 | $0 |
| Andrew J Murphy | — | 9. Dezember 2020 A | 57.350 | 0 | 0 | $0 |
| Robert E Landry | — | 9. Dezember 2020 A | 25.903 | 0 | 0 | $0 |
| Neil Stahl | — | 9. Dezember 2020 A | 24.715 | 0 | 0 | $0 |
| Bonnie L Bassler | — | 19. Juni 2020 M | 643 | 0 | 0 | $0 |
| VAGELOS P ROY | — | 16. Dezember 2019 I | 2.200 | 0 | 0 | $0 |
| Charles A Baker | — | 2. Januar 2018 A | 9.000 | 0 | 0 | $0 |
| Robert J Terifay | — | 12. Dezember 2017 A | 23.293 | 0 | 0 | $0 |
| Michael S Aberman | — | 16. Dezember 2016 A | 16.498 | 0 | 0 | $0 |
| Peter Powchik | — | 16. Dezember 2016 A | 2.459 | 0 | 0 | $0 |
| Douglas S Mccorkle | — | 29. Dezember 2015 M | 6.866 | 0 | 0 | $0 |
| Alfred G Gilman | — | 6. August 2015 M | 8.912 | 0 | 0 | $0 |
| Robert Alexander Ingram | — | 22. Mai 2015 M | 1.500 | 0 | 0 | $0 |
| Murray A Goldberg | — | 16. Dezember 2014 A | 64.436 | 0 | 0 | $0 |
| Eric M Shooter | — | 12. Februar 2014 M | 0 | 0 | 0 | $0 |
| William Roberts | — | 18. September 2013 M | 13.447 | 0 | 0 | $0 |
| Stuart Kolinski | — | 3. Juni 2010 M | 16.329 | 0 | 0 | $0 |
| Peter Dworkin | — | 18. Dezember 2009 A | — | 0 | 0 | $0 |
| Randall Rupp | — | 13. April 2007 M | 3.983 | 0 | 0 | $0 |
| Hans Peter Guler | — | 8. Oktober 2004 M | 10.530 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 2 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC., SYMPHONY ACQUISITION SUB, INC. ×2 Einreichungen | 27. September 2023 | — | Erste Einreichung | — | SEC |
| Sanofi ×17 Einreichungen | 17. Juni 2020 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 246 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| TBXU · Direxion Shares ETF Trust | 8,55% | 357 NS | 30. April 2026 | N-PORT |
| IBB · iShares Trust | 5,88% | 754.481 SH | 21. August 2026 | Täglich |
| PBE · Invesco Exchange-Traded Fund Trust | 5,50% | 26.441 SH | 21. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 5,49% | 6.065 SH | 21. August 2026 | Täglich |
| IDNA · iShares Trust | 3,88% | 11.531 SH | 21. August 2026 | Täglich |
| PJP · Invesco Exchange-Traded Fund Trust | 3,21% | 20.530 SH | 21. August 2026 | Täglich |
| BIB · ProShares Trust | 3,21% | 3.840 NS | 31. Mai 2026 | N-PORT |
| QQQA · ProShares Trust | 2,93% | 2.168 NS | 31. Mai 2026 | N-PORT |
| FTXH · First Trust Exchange-Traded Fund VI | 2,72% | 1.579 NS | 30. Juni 2026 | N-PORT |
| AGNG · Global X Funds | 2,48% | 3.299 NS | 31. Mai 2026 | N-PORT |
| SDG · iShares Trust | 2,36% | 5.119 SH | 21. August 2026 | Täglich |
| FBT · First Trust Exchange-Traded Fund | 2,25% | 101.350 NS | 30. Juni 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 2,19% | 344 NS | 30. April 2026 | N-PORT |
| QQQG · Pacer Funds Trust | 2,18% | 348 NS | 30. April 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,99% | 19.730 SH | 21. August 2026 | Täglich |
| QQEW · First Trust Exchange-Traded Fund | 1,99% | 57.866 NS | 30. Juni 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,98% | 24.491 NS | 30. April 2026 | N-PORT |
| QQXT · First Trust Exchange-Traded Fund | 1,89% | 5.032 NS | 30. Juni 2026 | N-PORT |
| SGLC · RBB Fund, Inc. | 1,87% | 5.922 NS | 31. Mai 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,78% | 1.346 NS | 30. April 2026 | N-PORT |
| PWV · Invesco Exchange-Traded Fund Trust | 1,70% | 38.010 SH | 21. August 2026 | Täglich |
| TECB · iShares Trust | 1,68% | 9.957 SH | 21. August 2026 | Täglich |
| HRTS · Tema ETF Trust | 1,67% | 1.408 NS | 31. Mai 2026 | N-PORT |
| QNXT · iShares Trust | 1,54% | 539 SH | 21. August 2026 | Täglich |
| BBP · ETFis Series Trust I | 1,52% | 1.276 NS | 30. April 2026 | N-PORT |
| RILA · Spinnaker ETF Series | 1,44% | 854 NS | 30. April 2026 | N-PORT |
| COWG · Pacer Funds Trust | 1,40% | 43.095 NS | 30. April 2026 | N-PORT |
| IYH · iShares Trust | 1,29% | 60.293 SH | 21. August 2026 | Täglich |
| FLAG · Global X Funds | 1,29% | 30 NS | 30. April 2026 | N-PORT |
| NUGO · Nushares ETF Trust | 1,27% | 50.872 NS | 30. April 2026 | N-PORT |
| GMOV · GMO ETF Trust | 1,19% | 1.758 NS | 31. Mai 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,19% | 4.569 NS | 30. April 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 1,18% | 47.616 NS | 30. April 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,17% | 299.615 NS | 30. April 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 1,16% | 770 NS | 30. April 2026 | N-PORT |
| IMCV · iShares Trust | 1,14% | 16.376 SH | 21. August 2026 | Täglich |
| CURE · Direxion Shares ETF Trust | 1,03% | 2.010 NS | 30. April 2026 | N-PORT |
| RND · First Trust Exchange-Traded Fund VI | 1,03% | 79 NS | 30. Juni 2026 | N-PORT |
| IXJ · iShares Trust | 1,00% | 52.534 SH | 21. August 2026 | Täglich |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,99% | 444 NS | 30. April 2026 | N-PORT |
| CVAR · ETF Opportunities Trust | 0,99% | 540 NS | 30. April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,95% | 312.338 SH | 19. August 2026 | Täglich |
| FLCV · Federated Hermes ETF Trust | 0,90% | 1.412 NS | 31. Mai 2026 | N-PORT |
| RXL · ProShares Trust | 0,90% | 1.051 NS | 31. Mai 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,87% | 14.942 NS | 30. April 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,85% | 6.267 NS | 30. April 2026 | N-PORT |
| RDVY · First Trust Exchange-Traded Fund VI | 0,85% | 334.208 NS | 30. Juni 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0,79% | 87 NS | 31. Mai 2026 | N-PORT |
| TAX · EA Series Trust | 0,78% | 324 NS | 29. Mai 2026 | N-PORT |
| QIDX · Spinnaker ETF Series | 0,77% | 419 NS | 30. April 2026 | N-PORT |